Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07277582 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Efficacy and Safety of THRV-1268 in Long QT Syndrome Type 2 (LQTS 2)
A Phase 2 study of Long QT Syndrome (LQTS) 2, sponsored by Thryv Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
- 6
- Study locations
NCT07277582: Recruiting Phase 2 study of Long QT Syndrome (LQTS) 2, sponsored by Thryv Therapeutics.
NCT07277582 is a Phase 2 study of Long QT Syndrome (LQTS) 2 that is actively recruiting participants, run by Thryv Therapeutics. The registered enrollment target is 64 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (52% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07277582, a Phase 2 study of Long QT Syndrome (LQTS) 2, is actively recruiting participants, sponsored by Thryv Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
- 6
- Study locations
Study Summary
The goal of this clinical trial is to learn whether the study drug THRV-1268 can safely and effectively shorten the QT interval in people diagnosed with Long QT Syndrome Type 2 (LQTS 2). The study will also learn about the safety and tolerability of THRV-1268 at different doses. The main questions this study aims to answer are: Does THRV-1268 reduce the QTc interval (a measure of the heart's electrical recovery time)? What side effects or medical problems occur when participants take THRV-1268? Which dose of THRV-1268 works best and is safest? Participants will: Complete a 3-week observation period with ECG and Holter monitoring to establish baseline QTc measurements Take THRV-1268 tablets twice daily at two dose levels for 6 weeks (Part A) or be randomly assigned to a dose group for 6 weeks (Part B) Have clinic visits and tests to monitor safety and changes in their heart rhythm May continue taking THRV-1268 for up to 1 year for ongoing safety and efficacy evaluation Researchers will compare changes in QTc over time and evaluate side effects to determine whether THRV-1268 can help reduce the risk of abnormal heart rhythms and sudden cardiac events in people with LQTS 2.
Primary Outcome
ΔAUC0-6 hours QTcF values on Day 42 (THRV-1268 50 mg BID) and Day 84 (THRV-1268 100 mg BID) compared to the the baseline (mean of Day -7 and Day -1).
Conditions Studied
Interventions
- OTHER baseline lead-in
- DRUG THRV-1268
Study Locations (6)
Arizona
- Honor Health Research and Innovation Institute - Scottsdale
California
- University of California San Francisco - San Francisco
Illinois
- University of Illinois Chicago - Chicago
Massachusetts
- Heart Center Clinical Research Program | MGH - Boston
Minnesota
- Mayo Clinic - Rochester
North Carolina
- Wilmington Health - Wilmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2026-03-31 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 2 |
What NCT07277582 shows while recruiting
NCT07277582 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (52% lower).
The record links to 1 condition, with Long QT Syndrome (LQTS) 2 appearing as the primary indexed condition, and to 2 interventions - of which baseline lead-in is the first listed.
NCT07277582 lists 6 locations in 6 states (Arizona, California, Illinois).
Frequently Asked Questions
What is clinical trial NCT07277582 about?
NCT07277582 is a clinical study titled "Evaluation of Efficacy and Safety of THRV-1268 in Long QT Syndrome Type 2 (LQTS 2)". The goal of this clinical trial is to learn whether the study drug THRV-1268 can safely and effectively shorten the QT interval in people diagnosed with Long QT Syndrome Type 2 (LQTS 2). The study will also learn about the safety and tolerability of THRV-1268 at different doses. The main questions ...
What is the current status of trial NCT07277582?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2026-03-31. Estimated completion is 2027-06-30.
What conditions does trial NCT07277582 study?
This clinical trial studies the following conditions: Long QT Syndrome (LQTS) 2.
What interventions are being tested in trial NCT07277582?
The interventions under investigation include: baseline lead-in (OTHER), THRV-1268 (DRUG).
Who is sponsoring clinical trial NCT07277582?
This trial is sponsored by Thryv Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07277582 being conducted?
This trial has 6 study locations across Arizona, California, Illinois, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07277582's enrollment target sits among peer trials
64 996th of 2000 higher than 993 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI